NASDAQ · Biotechnology

HRMY (HRMY) Stock

$40.29 +2.31% NASDAQ: HRMY Healthcare

Valuation

MetricValue
Price$40.29
Market Cap$2.33B
P/E Ratio11.23
P/B Ratio2.03
P/S Ratio1.96
EPS (TTM)$2.71
52-Week High$40.87
52-Week Low$25.52
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE18.28%
ROA12.50%
ROCE23.88%
Gross Margin23.96%
Operating Margin23.96%
Net Margin16.20%
Debt/Equity0.23
Current Ratio3.60

Annual Financials (USD)

Metric20212022202320242025
Revenue$305.0M$438.0M$582.0M$715.0M$868.0M
Operating Profit$88.0M$120.0M$192.0M$191.0M$208.0M
Net Profit$35.0M$181.0M$129.0M$145.0M$159.0M
EPS$0.58$2.97$2.13$2.51$2.71
Op Margin28.7%27.4%33.0%26.7%24.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$433.0M$674.0M$811.0M$999.0M$1.3B
Total Liabilities$247.0M$271.0M$344.0M$340.0M$401.0M
Cash$234.0M$244.0M$312.0M$453.0M$753.0M
Borrowings$196.0M$192.0M$194.0M$181.0M$240.0M

Latest News

Deutsche Bank Adjusts Price Target on Harmony Biosciences to $36 From $30, Maintains Hold Rating MT Newswires · Jun 30, 2026 Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? Zacks · Jun 29, 2026 HRMY Growth Trends Beyond Wakix Could Shape Its Next Growth Phase Zacks · Jun 29, 2026 Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline Zacks · Jun 29, 2026 Harmony Biosciences (HRMY) Stock Valuation After New Pitolisant Data And Reaffirmed Guidance Simply Wall St. · Jun 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$99.0M$144.0M$219.0M$220.0M$348.0M
Investing Cash Flow$-101.0M$-142.0M$-47.0M$-69.0M$-40.0M
Financing Cash Flow$8.0M$9.0M$-104.0M$-2.0M$-3.0M
Net Cash Flow$6.0M$9.0M$67.0M$141.0M$300.0M
Free Cash Flow$98.0M$144.0M$219.0M$219.0M$348.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA5.36
FCF Yield19.40%
Quick Ratio3.56
Interest Coverage13.87
Return 1Y-4.99%
Return 3Y-2.11%
Return 5Y18.45%

Ownership

Insiders Held11.69%
Institutions Held103.37%
Institutions Float Held117.05%
Institutional HolderSharesReport Date
Blackrock Inc.7,070,0352026-03-31
FMR, LLC3,157,6392026-03-31
Vanguard Portfolio Management LLC2,714,3532026-03-31
American Century Companies Inc2,105,1792026-03-31
Vanguard Capital Management LLC2,102,3152026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABCL $11.14 -2.96% -21.26 $3.40B 0.00%
AUPH $16.02 -0.59% 7.46 $2.06B 0.00%
BHVN $15.96 +4.52% -6.11 $2.40B 0.00%
CLDX $39.21 -1.06% -7.84 $2.61B 0.00%
IMCRImmunocore Holdings plc $31.95 -3.42% -85.34 $1.62B 0.00%

About HRMY

HRMY stock trades at $40.29 with a market capitalization of $2.33B. The stock is valued at a price-to-earnings (P/E) ratio of 11.23, price-to-book of 2.03, price-to-sales of 1.96. Over the past 52 weeks the stock has ranged between $25.52 and $40.87, and currently trades 1.4% below its 52-week high.

On profitability, HRMY generates a return on equity (ROE) of 18.28%, above the typical market average, return on capital employed of 23.88%, an operating margin of 23.96%, a net profit margin of 16.20%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1158.17 +0.12% JNJ Drug Manufacturers - General $270.47 +1.74% ABBV Drug Manufacturers - General $260.17 +1.46% MRK Drug Manufacturers - General $149.73 +1.33% UNH Medical - Healthcare Plans $395.82 +1.65% NVS Drug Manufacturers - General $161.42 +6.16% AZN Drug Manufacturers - General $161.93 -0.12% AMGN Drug Manufacturers - General $435.89 +1.40% TMO Medical - Diagnostics & Research $601.92 -2.46% NVO Biotechnology $45.15 -0.41% ABT Medical - Devices $109.15 -1.10% GILD Drug Manufacturers - General $148.93 +1.77%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides